Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism

References

• Adams AIH, Gosmann G, Schneider PH, Bergold AM. 2009. LC stability studies of voriconazole and structural elucidation of its major degradation product. Chroma. 69:115–122.
   Web of Science ®Google Scholar
• Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, De Nicolò A, Cusato J, Di Perri G, D'Avolio A, et al. 2018. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. Br J Clin Pharmacol. 84:197–203.
   PubMed Web of Science ®Google Scholar
• Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. 2014. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 69:1162–1176.
   PubMed Web of Science ®Google Scholar
• Barbarino JM, Owusu Obeng A, Klein TE, Altman RB. 2017. PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenet Genomics. 27:201–209.
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Wolfs T, Jonker M, et al. 2013. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 57:235–240.
   PubMed Web of Science ®Google Scholar
• Batchelor HK, Marriott JF. 2013. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 79:395–404.
   Web of Science ®Google Scholar
• Bourcier K, Hyland R, Kempshall S, Jones R, Maximilien J, Irvine N, Jones B. 2010. Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 38:923–929.
   PubMed Web of Science ®Google Scholar
• Boyd NK, Zoellner CL, Swancutt MA, Bhavan KP. 2012. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections. Antimicrob Agents Chemother. 56:6001–6002.
   PubMed Web of Science ®Google Scholar
• Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. 2006. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother. 50:2455–2463.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, et al. 2016. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 19:215–223.
   PubMed Web of Science ®Google Scholar
• Celik IH, Demirel G, Oguz SS, Uras N, Erdeve O, Dilmen U. 2013. Compassionate use of voriconazole in newborn infants diagnosed with severe invasive fungal sepsis. Eur Rev Med Pharmacol Sci. 17:729–734.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhu L, Li M, Li N, Qi F, Wang N. 2019. Predicting the effects of different triazole antifungal agents on the pharmacokinetics of tamoxifen. AAPS PharmSciTech. 20:24.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, Pigneux A, Cornely OA, Ullmann AJ, Bofarull RM, et al. 2010. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 95:1762–1768.
   PubMed Web of Science ®Google Scholar
• Damle B, Varma MV, Wood N. 2011. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrob Agents Chemother. 55:5172–5177.
   PubMed Web of Science ®Google Scholar
• Desta Z, Metzger IF, Thong N, Lu JBL, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE. 2016. Inhibition of cytochrome P450 2B6 activity by voriconazole profiled using efavirenz disposition in healthy volunteers. Antimicrob Agents Chemother. 60:6813–6822.
   PubMed Web of Science ®Google Scholar
• Doby EH, Benjamin DK, Blaschke AJ, Ward RM, Pavia AT, Martin PL, Driscoll TA, Cohen-Wolkowiez M, Moran C. 2012. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J. 31:632–635.
   PubMed Web of Science ®Google Scholar
• Dolton MJ, McLachlan AJ. 2014. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents. 44:183–193.
   PubMed Web of Science ®Google Scholar
• Dowell JA, Schranz J, Baruch A, et al. 2005. Safety and Pharmacokinetics of Coadministered Voriconazole and Anidulafungin. J Clin Pharmacol. 45:1373–1382.
   PubMed Web of Science ®Google Scholar
• Dressman JB, Thelen K. 2009. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 61:541–558.
   PubMed Web of Science ®Google Scholar
• Duflot T, Schrapp A, Bellien J, Lamoureux F. 2018. Impact of CYP3A4 genotype on voriconazole exposure. Clin Pharmacol Ther. 103:185–186.
   PubMed Web of Science ®Google Scholar
• Eljaaly K, Nix DE. 2016. Voriconazole dosing in obese patients. Clin Infect Dis. 63:286–287.
   PubMed Web of Science ®Google Scholar
• Encalada Ventura MA, Span LFR, van den Heuvel ER, Groothuis GMM, Alffenaar J-WC. 2015. Influence of inflammation on voriconazole metabolism. Antimicrob Agents Chemother. 59:2942–2943.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2012. European public assessment reports: VFEND, 1–154.
   Google Scholar
• European Pharmacopoeia Commission. 2016. European pharmacopoeia. 9th ed. Strasbourg: Council of Europe.
   Google Scholar
• Ferguson MJ, Randles ML, de Freitas DG. 2017. A suspected case of autoinduction of voriconazole metabolism in a patient with cerebral aspergillosis. Drug Healthc Patient Saf. 9:89–91.
   PubMed Web of Science ®Google Scholar
• Fihlman M, Hemmilä T, Hagelberg NM, Kuusniemi K, Backman JT, Laitila J, Laine K, Neuvonen PJ, Olkkola KT, Saari TI, et al. 2016. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacol. 72:1363–1371.
   PubMed Web of Science ®Google Scholar
• Friberg LE, Ravva P, Karlsson MO, Liu P. 2012. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 56:3032–3042.
   PubMed Web of Science ®Google Scholar
• Gautier-Veyret E, Bailly S, Fonrose X, Tonini J, Chevalier S, Thiebaut-Bertrand A, Stanke-Labesque F. 2017. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations. Pharmacogenomics. 18:1119–1123.
   PubMed Web of Science ®Google Scholar
• Gautier-Veyret E, Fonrose X, Stanke-Labesque F. 2017. Pharmacogenetics of voriconazole: CYP2C19 but also CYP3A4 need to be genotyped. Clin Pharmacol Ther. 102:189.
   PubMed Web of Science ®Google Scholar
• Gautier‐Veyret E, Truffot A, Bailly S, Fonrose X, Thiebaut‐Bertrand A, Tonini J, Cahn J‐Y, Stanke‐Labesque F. 2018. Inflammation is a potential risk factor of voriconazole overdose in hematological patients. Fundam Clin Pharmacol. 33:232–238.
   PubMed Web of Science ®Google Scholar
• Geist MJP, Egerer G, Burhenne J, Mikus G. 2006. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype [4]. Antimicrob Agents Chemother. 50:3227–3228.
   PubMed Web of Science ®Google Scholar
• Geist MJP, Egerer G, Burhenne J, Riedel K-D, Mikus G. 2007. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother. 51:3455–3456.
   PubMed Web of Science ®Google Scholar
• Geist MJP, Egerer G, Burhenne J, Riedel K-D, Weiss J, Mikus G. 2013. Steady-state pharmacokinetics and metabolism of voriconazole in patients. J Antimicrob Chemother. 68:2592–2599.
   PubMed Web of Science ®Google Scholar
• Germovsek E, Barker CIS, Sharland M, Standing JF. 2017. Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful? Br J Clin Pharmacol. 83:777–790.
   PubMed Web of Science ®Google Scholar
• Giri P, Naidu S, Patel N, Patel H, Srinivas NR. 2017. Evaluation of in vitro cytochrome P450 inhibition and in vitro fate of structurally diverse N-oxide metabolites: case studies with clozapine, levofloxacin, roflumilast, voriconazole and zopiclone. Eur J Drug Metab Pharmacokinet. 42:677–688.
   PubMed Web of Science ®Google Scholar
• Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman A-H, Brüggemann RJM. 2017. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 19:e12751–11.
   Web of Science ®Google Scholar
• Han K, Capitano B, Bies R, Potoski BA, Husain S, Gilbert S, Paterson DL, McCurry K, Venkataramanan R. 2010. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother. 54:4424–4431.
   PubMed Web of Science ®Google Scholar
• Hassan A, Burhenne J, Riedel K-D, Weiss J, Mikus G, Haefeli WE, Czock D. 2011. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit. 33:86–93.
   PubMed Web of Science ®Google Scholar
• Hayton WL. 2002. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci. 2:E3.
   Google Scholar
• Hines RN, McCarver DG. 2002. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther. 300:355–360.
   PubMed Web of Science ®Google Scholar
• Hines RN. 2007. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 21:169–175.
   PubMed Web of Science ®Google Scholar
• Hines RN. 2013. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm. 452:3–7.
   PubMed Web of Science ®Google Scholar
• Hohmann N, Kocheise F, Carls A, Burhenne J, Weiss J, Haefeli WE, Mikus G. 2016. Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole. Clin Pharmacokinet. 55:1535–1545.
   PubMed Web of Science ®Google Scholar
• Hohmann N, Kreuter R, Blank A, Weiss J, Burhenne J, Haefeli WE, Mikus G. 2017. Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. Br J Clin Pharmacol. 83:1954–1965.
   PubMed Web of Science ®Google Scholar
• Hsu AJ, Dabb A, Arav-Boger R. 2015. Autoinduction of voriconazole metabolism in a child with invasive pulmonary aspergillosis. Pharmacotherapy. 35:e20–e26.
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 31:540–547.
   PubMed Web of Science ®Google Scholar
• Jeong S, Nguyen PD, Desta Z. 2009. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 53:541–551.
   PubMed Web of Science ®Google Scholar
• Johnson TN, Rostami-Hodjegan A, Tucker GT. 2006. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 45:931–956.
   PubMed Web of Science ®Google Scholar
• Karlsson MO, Lutsar I, Milligan PA. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 53:935–944.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 349:1157–1167.
   PubMed Web of Science ®Google Scholar
• Kees MG, Wicha SG, Seefeld A, Kees F, Kloft C. 2014. Unbound fraction of vancomycin in intensive care unit patients. J Clin Pharmacol. 54:318–323.
   PubMed Web of Science ®Google Scholar
• Kirbs C, Kluwe F, Drescher F, Lackner E, Matzneller P, Weiss J, Zeitlinger M, Kloft C. 2019. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. Eur J Pharm Sci. 131:218–229.
   PubMed Web of Science ®Google Scholar
• Kofla G, Ruhnke M. 2005. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother. 6:1215–1229.
   PubMed Web of Science ®Google Scholar
• Koselke E, Kraft S, Smith J, Nagel J. 2012. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother. 67:2957–2962.
   PubMed Web of Science ®Google Scholar
• Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. 2003. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 308:965–974.
   PubMed Web of Science ®Google Scholar
• Koukouritaki SB, Simpson P, Yeung CK. 2002. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res. 51:236–243.
   PubMed Web of Science ®Google Scholar
• Leeder JS, Kearns GL, Spielberg SP, van den Anker J. 2010. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol. 50:1377–1387.
   PubMed Web of Science ®Google Scholar
• Lempers VJC, van den Heuvel JJMW, Russel FGM, Aarnoutse RE, Burger DM, Brüggemann RJ, Koenderink JB. 2016. Inhibitory potential of antifungal drugs on ATP-binding cassette transporters P-glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother. 60:3372–3379.
   PubMed Web of Science ®Google Scholar
• Li M, Zhu L, Chen L, Li N, Qi F. 2018. Assessment of drug-drug interactions between voriconazole and glucocorticoids. J Chemother. 30:296–303.
   PubMed Web of Science ®Google Scholar
• Li N, Zhu L, Qi F, Li M, Xu G, Ge T. 2018. Prediction of the effect of voriconazole on the pharmacokinetics of non-steroidal anti-inflammatory drugs. J Chemother. 30:240–246.
   PubMed Web of Science ®Google Scholar
• Li T-Y, Liu W, Chen K, Liang S-Y, Liu F. 2017. The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review. J Clin Pharm Ther. 42:135–146.
   PubMed Web of Science ®Google Scholar
• Lin X-B, Li Z-W, Yan M, Zhang B-K, Liang W, Wang F, Xu P, Xiang D-X, Xie X-B, Yu S-J, et al. 2018. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol. 84:1587–1597.
   PubMed Web of Science ®Google Scholar
• Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, Sharma A. 2007. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother. 51:3617–3626.
   PubMed Web of Science ®Google Scholar
• Luo X, Li T, Yu Z, et al. 2019. The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes. Xenobiotica. 49:753–761.
   PubMed Web of Science ®Google Scholar
• Lutsar I, Roffey S, Troke P. 2003. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 37:728–732.
   PubMed Web of Science ®Google Scholar
• Maharaj AR, Gonzalez D, Cohen-Wolkowiez M, et al. 2017 Aug. Improving pediatric protein binding estimates: an evaluation of α1-acid glycoprotein maturation in healthy and infected subjects. Clin Pharmacokinet. 57:577–589.
   Web of Science ®Google Scholar
• Mahmood I. 2014. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet. 53:327–346.
   PubMed Web of Science ®Google Scholar
• Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel C-P, Kantecki M, Miller PJS, Ribaud P, Schlamm HT, Solano C, et al. 2011. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 155:318–327.
   PubMed Web of Science ®Google Scholar
• McNamara PJ, Alcorn J. 2002. Protein binding predictions in infants. AAPS PharmSci. 4:19–26.
   Google Scholar
• Michelet R, Van Bocxlaer J, Vermeulen A. 2018. PBPK in preterm and term neonates: a review. Curr Pharm Des. 23:5943–5954.
   Web of Science ®Google Scholar
• Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, Riedel K-D, Burhenne J, Weiss J, Thomsen T, Haefeli WE, et al. 2006. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther. 80:126–135.
   PubMed Web of Science ®Google Scholar
• Minichmayr IK, Schaeftlein A, Kuti JL, Zeitlinger M, Kloft C. 2017. Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients. Clin Pharmacokinet. 56:617–633.
   PubMed Web of Science ®Google Scholar
• Moody DE, Liu F, Fang WB. 2015. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism. J Anal Toxicol. 39:374–386.
   PubMed Web of Science ®Google Scholar
• Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez J, Wingard JR, McLeod HL, Klein TE, et al. 2017. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 102:45–51.
   PubMed Web of Science ®Google Scholar
• Morlière P, Silva AMS, Seixas RSGR, Boscá F, Mazière J-C, Ferreira J, Santus R, Filipe P. 2018. Photosensitisation by voriconazole-N-oxide results from a sequence of solvent and pH-dependent photochemical and thermal reactions. J Photochem Photobiol B Biol. 187:1–9.
   PubMed Web of Science ®Google Scholar
• Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. 2007. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 73:2020–2026.
   PubMed Web of Science ®Google Scholar
• Naito T, Yamada T, Mino Y, Kawakami J. 2015. Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients. Clin Chim Acta. 441:127–132.
   PubMed Web of Science ®Google Scholar
• Niece KL, Boyd NK, Akers KS. 2015. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother. 59:5548–5554.
   PubMed Web of Science ®Google Scholar
• Niwa T, Imagawa Y, Yamazaki H. 2014. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab. 15:651–679.
   PubMed Web of Science ®Google Scholar
• Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull. 28:1813–1816.
   PubMed Web of Science ®Google Scholar
• Niwa T, Shiraga T, Takagi A. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 28:1805–1808.
   PubMed Web of Science ®Google Scholar
• Ona K, Oh DH. 2015. Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A. Br J Dermatol. 173:751–759.
   PubMed Web of Science ®Google Scholar
• Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O. 2012. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 55:381–390.
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. 2010. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf. 9:125–137.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, et al. 2016. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 63:e1–e60.
   PubMed Web of Science ®Google Scholar
• Pearson MM, Rogers PD, Cleary JD, Chapman SW. 2003. Voriconazole: a new triazole antifungal agent. Ann Pharmacother. 37:420–432.
   PubMed Web of Science ®Google Scholar
• Pfizer. 2018. VFEND Summary of product characteristics.
   Google Scholar
• Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH. 2012. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother. 67:2717–2724.
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D. 2003. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol. 56:30–36.
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. 2003. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol. 56(Suppl 1):37–44.
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Kleinermans D, Nichols D. 2003. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol. 56(Suppl)1:24–29.
   PubMed Web of Science ®Google Scholar
• Qi F, Zhu L, Li N, Ge T, Xu G, Liao S. 2017. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents. 49:403–409.
   PubMed Web of Science ®Google Scholar
• Rengelshausen J, Banfield M, Riedel K, Burhenne J, Weiss J, Thomsen T, Waltersack I, Haefeli W, Mikus G. 2005. Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 78:25–33.
   PubMed Web of Science ®Google Scholar
• Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, Smith DA, Walker DK, Wood N. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 31:731–741.
   PubMed Web of Science ®Google Scholar
• Scholz I, Oberwittler H, Riedel K-D, Burhenne J, Weiss J, Haefeli WE, Mikus G. 2009. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 68:906–915.
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. 2015. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 43:400–410.
   PubMed Web of Science ®Google Scholar
• Shi C, Xiao Y, Mao Y, Wu J, Lin N. 2019. Voriconazole: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 58:687.
   PubMed Web of Science ®Google Scholar
• Simmel F, Kirbs C, Erdogan Z, Lackner E, Zeitlinger M, Kloft C. 2013. Pilot investigation on long-term subcutaneous microdialysis: proof of principle in humans. AAPS J. 15:95–103.
   PubMed Web of Science ®Google Scholar
• Simmel F, Kloft C. 2010. Microdialysis feasibility investigations with the non-hydrophilic antifungal voriconazole for potential applications in nonclinical and clinical settings. Int J Clin Pharmacol Ther. 48:695–704.
   PubMed Web of Science ®Google Scholar
• Simmel F, Soukup J, Zoerner A, Radke J, Kloft C. 2008. Development and validation of an efficient HPLC method for quantification of voriconazole in plasma and microdialysate reflecting an important target site. Anal Bioanal Chem. 392:479–488.
   PubMed Web of Science ®Google Scholar
• Smits A, Annaert P, Allegaert K. 2013. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. Int J Pharm. 452:8–13.
   PubMed Web of Science ®Google Scholar
• Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, Manns MP. 2002. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 50:259–265.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. 2006. Pharmacokinetic/pharmacodynamic profile of Voriconazole. Clin Pharmacokinet. 45:649–663.
   PubMed Web of Science ®Google Scholar
• Tucker L, Higgins T, Egelund EF, Zou B, Vijayan V, Peloquin CA. 2015. Voriconazole monitoring in children with invasive fungal infections. J Pediatr Pharmacol Ther. 20:17–23.
   PubMedGoogle Scholar
• Turner RB, Martello JL, Malhotra A. 2015. Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: a systematic review. Int J Antimicrob Agents. 46:362–366.
   PubMed Web of Science ®Google Scholar
• Upreti VV, Wahlstrom JL. 2016. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 56:266–283.
   PubMed Web of Science ®Google Scholar
• Vadlapatla RK, Patel M, Paturi DK, Pal D, Mitra AK. 2014. Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Expert Opin Drug Metab Toxicol. 10:561–580.
   PubMed Web of Science ®Google Scholar
• Van Booven D, Marsh S, McLeod H, et al. 2010. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 20:1.
   PubMed Web of Science ®Google Scholar
• Vanstraelen K, Wauters J, De Loor H, Vercammen I, Annaert P, Lagrou K, Spriet I. 2014. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J Pharm Sci. 103:2565–2570.
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Zang S, Gayowski T, Singh N. 2002. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother. 46:3091–3093.
   PubMed Web of Science ®Google Scholar
• Veringa A, ter Avest M, Span LFR, van den Heuvel ER, Touw DJ, Zijlstra JG, Kosterink JGW, van der Werf TS, Alffenaar J-WC. 2017. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 72:261–267.
   PubMed Web of Science ®Google Scholar
• Veringa A, Geling S, Span LFR, Vermeulen KM, Zijlstra JG, van der Werf TS, Kosterink JGW, Alffenaar J-WC. 2017. Bioavailability of voriconazole in hospitalised patients. Int J Antimicrob Agents. 49:243–246.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil B, van der Velden WJFM, Feuth T, Kox M, Pickkers P, van de Veerdonk FL, Blijlevens NMA, Brüggemann RJM. 2018. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Br J Clin Pharmacol. 84:1980–1988.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, et al. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 48:2166–2172.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Moriyama B, Penzak SR, Klein TE, Caudle KE. 2017. Response to “pharmacogenetics of voriconazole: CYP2C19 but also CYP3A4 need to be genotyped - the role of CYP3A4 and CYP3A5 polymorphisms in clinical pharmacokinetics of voriconazole”. Clin Pharmacol Ther. 102:190.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Moriyama B, Penzak SR, Klein TE, Caudle KE. 2018. Response to “impact of CYP3A4 genotype on voriconazole exposure: new insights into the contribution of CYP3A4*22 to metabolism of voriconazole.”. Clin Pharmacol Ther. 103:187.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, Ryder TF, Obach RS, Hyland R, Goosen TC, et al. 2012. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos. 40:1051–1065.
   PubMed Web of Science ®Google Scholar
• Wang T, Chen S, Sun J, Cai J, Cheng X, Dong H, Wang X, Xing J, Dong W, Yao H, et al. 2014. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother. 69:463–470.
   PubMed Web of Science ®Google Scholar
• Wang T, Yan M, Tang D, Xue L, Zhang T, Dong Y, Zhu L, Wang X, Dong Y. 2018a. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis. J Clin Pharm Ther. 43:849–854.
   PubMed Web of Science ®Google Scholar
• Wang T, Yan M, Tang D, Xue L, Zhang T, Dong Y, Zhu L, Wang X, Dong Y. 2018b. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: a multicenter study. Int J Infect Dis. 72:49–54.
   PubMed Web of Science ®Google Scholar
• Van Wanrooy MJP, Span LFR, Rodgers MGG, et al. 2014. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 58:7099–7101.
   Web of Science ®Google Scholar
• Werk AN, Cascorbi I. 2014. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 96:340–348.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2017a. WHO model list of essential medicines.
   Google Scholar
• World Health Organization. 2017b. WHO model list of essential medicines for children.
   Google Scholar
• Yamada T, Imai S, Koshizuka Y, Tazawa Y, Kagami K, Tomiyama N, Sugawara R, Yamagami A, Shimamura T, Iseki K, et al. 2018. Necessity for a significant maintenance dosage reduction of voriconazole in patients with severe liver cirrhosis (Child–Pugh Class C). Biol Pharm Bull. 41:1112–1118.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T. 2010. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol. 69:593–597.
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. 2007. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab. 8:676–684.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK, Thakker DR. 2008. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 36:1119–1125.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK, Thakker DR. 2010. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 38:25–31.
   PubMed Web of Science ®Google Scholar
• Yasu T, Konuma T, Kato S, Kurokawa Y, Takahashi S, Tojo A. 2017. Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. Leuk Lymphoma. 58:2731–2733.
   PubMed Web of Science ®Google Scholar
• Zane NR, Thakker DR. 2014. A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children. Clin Pharmacokinet. 53:1171–1182.
   PubMed Web of Science ®Google Scholar
• Zhang S, Pillai VC, Mada SR, Strom S, Venkataramanan R. 2012. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica. 42:409–416.
   PubMed Web of Science ®Google Scholar
• Zhu L, Brüggemann RJ, Uy J, Colbers A, Hruska MW, Chung E, Sims K, Vakkalagadda B, Xu X, van Schaik RHN, et al. 2017. CYP2C19 genotype-dependent pharmacokinetic drug interaction between voriconazole and ritonavir-boosted atazanavir in healthy subjects. J Clin Pharmacol. 57:235–246.
   PubMed Web of Science ®Google Scholar
• Zonios D, Yamazaki H, Murayama N, Natarajan V, Palmore T, Childs R, Skinner J, Bennett JE. 2014. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 209:1941–1948.
   PubMed Web of Science ®Google Scholar